Search Results
Your search for The,The matches 35255 pages
Showing 12301 - 12350Nonmetastatic Castration-Resistant Prostate Cancer
Nonmetastatic castration-resistant prostate cancer arises in the subset of men with biochemically recurrent disease (ie, rising prostate-specific antigen [PSA] level after definitive therapy in the absence of metastases) who develop PSA progression after chronic exposure to androgen-deprivation...
Phase III Study of AR Antagonist in Nonmetastatic Castration-Resistant Prostate Cancer
In the phase III ARAMIS trial reported in The New England Journal of Medicine,1 Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Universite Paris-Sud, Villejuif, France, and colleagues found that the androgen-receptor (AR) antagonist darolutamide significantly prolonged metastasis-free...
Novel Indications and New Drugs for Castration-Resistant or Castrate-Sensitive Prostate Cancer
The past year has witnessed the U.S. Food and Drug Administration (FDA) approval of a number of drugs for treatment of patients with metastatic castrate-resistant prostate cancer or castrate-sensitive prostate cancer. Castrate-Resistant Prostate Cancer Olaparib: On May 19, 2020, olaparib...
Phase II TRITON2 Study in Metastatic Castration-Resistant Prostate Cancer
The single-arm TRITON2 study demonstrated the efficacy of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer.1,2 Results from the study (ClinicalTrials.gov identifier NCT02952534) led to the approval of rucaparib in this...
Final Analysis of the ARAMIS Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer
A year ago, initial results from the double-blind, multicenter, randomized phase III ARAMIS clinical trial evaluating the efficacy and safety of darolutamide, a structurally unique androgen-receptor antagonist, in men with nonmetastatic castration-resistant prostate cancer, were published in The...
Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer
In the final overall survival analysis of the phase III PROSPER trial reported at the ASCO20 Virtual Scientific Program1 and published in The New England Journal of Medicine,2 Cora N. Sternberg, MD, and colleagues found that enzalutamide plus androgen-deprivation therapy (ADT) significantly...
Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial
As reported at the ASCO20 Virtual Scientific Program1 and in The New England Journal of Medicine2 by Neal D. Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, South Carolina, and colleagues, the phase III HERO trial showed sustained castrate testosterone levels and lower risk of...
In Biochemically Recurrent Prostate Cancer, PSMA-Targeted PET/CT Imaging May Be Useful
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial of any PSMA-targeted therapy and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...
Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer
Initial results of the randomized phase II TheraP trial showed that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177–labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic...
Genitourinary Oncology Highlights 2019–2020 Almanac
Over the past year, we have seen significant advances in the treatment of prostate, kidney, and urothelial cancers that will benefit patients now and in the future. We have learned about the final results of important clinical trials across multiple genitourinary cancers disease states leading to...
Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities
Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus...
Kala Visvanathan, MD, on Ovarian Cancer: Lowering Mortality With Lipophilic Statins
Kala Visvanathan, MD, of Johns Hopkins Bloomberg School of Public Health, discusses her analysis of data from more than 10,000 women with ovarian cancer. The results suggest that atorvastatin and simvastatin, lipophilic statin cholesterol-lowering drugs, reduced ovarian cancer death rates (Abstract ...
ASH Releases New Clinical Practice Guidelines on the Treatment of Older Adults With Newly Diagnosed Acute Myeloid Leukemia
The American Society of Hematology (ASH) has published new guidelines to help older adults with acute myeloid leukemia (AML) and their health-care providers make critical care decisions, including if and how to proceed with cancer treatment and the need for blood transfusions for those in hospice...
Addition of Locoregional Radiotherapy to Chemotherapy for Metastatic Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in JAMA Oncology, You et al found that the addition of locoregional radiotherapy to chemotherapy improved overall survival in patients with chemotherapy-sensitive metastatic nasopharyngeal carcinoma. Study Details The open-label trial included 126 previously...
UICC Applauds WHO Global Strategy on Eliminating Cervical Cancer as a Public Health Problem
The Union for International Cancer Control (UICC) lauded the adoption of the World Health Organization’s (WHO) global strategy toward eliminating cervical cancer as a public health problem. WHO Member States adopted the strategy alongside other health resolutions as part of the silence procedure...
Pembrolizumab Monotherapy as First-Line Treatment for Patients With Unresectable Cutaneous Squamous Cell Carcinoma
In the French phase II CARSKIN trial reported in the Journal of Clinical Oncology, Maubec et al found that pembrolizumab monotherapy produced durable responses in the first-line treatment of unresectable cutaneous squamous cell carcinoma. Study Details In the multicenter trial, 39 patients (primary ...
Effect of Molecular Classification of Endometrial Cancer on Adjuvant Therapy Outcomes
In a study reported in the Journal of Clinical Oncology, Léon-Castillo et al identified outcomes associated with molecular subgroups of patients with high-risk endometrial cancer enrolled in the PORTEC-3 trial of adjuvant chemoradiotherapy vs radiotherapy alone. Study Details The study involved...
Update on Detecting and Treating Biologically Diverse Neuroendocrine Tumors
Neuroendocrine tumors are rare malignancies that arise in neuroendocrine cells, which can occur throughout the body but are most commonly found in the gastrointestinal tract, lungs, and pancreas. Although most neuroendocrine tumors are indolent and take years to grow, some are aggressive and grow...
10-Year Study Indicates Pembrolizumab Provides Long-Term Benefits for Patients With Metastatic Melanoma
A new 10-year analysis, led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and recently published in JAMA Oncology,1 provides new insights into an important question: whether BRAF V600E/K–mutation status or ...
Managing the Cost of Cancer Care Can Be Overwhelming
A cancer diagnosis is often overwhelming in and of itself, and adding financial burdens to the mix can sometimes feel unmanageable. Provide your patients with practical guidelines with the Managing the Cost of Cancer Care booklet from ASCO Answers. It covers health insurance benefits, information...
CMS, CMMI Announce Flexibilities for Oncology Practices Impacted by COVID-19
The Centers for Medicare & Medicaid Services (CMS) recently announced flexibilities for clinicians participating in the 2020 Quality Payment Program (QPP) Merit-based Incentive Payment System (MIPS) who have been impacted by the COVID-19 Public Health Emergency (PHE). Affected clinicians may...
ASCO Conducting Open Search for Chief Medical Officer: Express Interest by August 21, 2020
ASCO is conducting an open search for the position of Chief Medical Officer and Executive Vice President, as current Chief Medical Officer Richard L. Schilsky, MD, FACP, FSCT, FASCO, prepares to retire in February 2021. ASCO’s Chief Medical Officer applies medical and scientific knowledge and...
Conquer Cancer Donors Provide Key Resources for Patients and Providers During the COVID-19 Pandemic
Before there was funding, there was a need. “Patients with cancer needed to understand immediately what COVID-19 meant [for] their health. Providers and practices needed guidance on how to offer safe care,” recalled Howard A. Burris III, MD, FACP, FASCO, Chair of the ASCO Board of Directors, of...
ASCO Special Report: Resuming Cancer Care Delivery During the COVID-19 Pandemic
I’m very pleased to be joined by Piyush Srivastava, MD, Past Chair of ASCO’s Clinical Practice Committee. Dr. Srivastava is a practicing gastrointestinal oncologist, Regional Medical Director of the End of Life Options Program, and Director of Outpatient Palliative Care at Kaiser Permanente Walnut...
Having Cancer Has Not Affected Me in Any Negative Way
I have witnessed much sickness and death over my 35-year career as a medical oncologist. During the early years of my career, I had difficulty dealing with the sickness and death I witnessed on a regular basis. As a result, with help from the Hindu scripture of Bhagavad Gita, I have trained my...
Stand Up To Cancer Announces New Research and Education Effort to Improve Care for Underserved Patients With Lung Cancer
Stand Up To Cancer (SU2C) recently announced a $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health-care equity for underserved patients with lung cancer, including Black individuals and those living in rural communities. The disease remains...
New Effort to Address Health Disparities for Black Men
The Prostate Cancer Foundation and Robert F. Smith, Founder, Chairman and Chief Executive Officer (CEO) of Vista Equity Partners, have announced a new effort to reduce deaths from prostate cancer, one of the largest health disparities facing Black men today. “As African American men are at an...
A Health-Care Journalist Explores Breast Cancer in America, Through the Lens of Her Own Diagnosis
Great strides in research and clinical practice have decreased breast cancer mortality rates by more than 35% since 1990, yet about 40,000 American women die of the disease each year. In Radical: The Science, Culture, and History of Breast Cancer in America, health-care journalist Kate Pickert...
Physicians, New Drugs, and Pharma
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have approved record numbers of new cancer drugs recently. This is extraordinarily good news for physicians, patients, and drug companies, but it raises important questions as to how effective these drugs are, whether...
Pembrolizumab for Cutaneous Squamous Cell Carcinoma
On June 24, 2020, pembrolizumab was approved for treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.1,2 Supporting Efficacy Data Approval was based on findings in the multicenter, multicohort, open-label KEYNOTE-629 trial ...
Florida Cancer Specialists Appoints New Chief Executive Officer
Florida Cancer Specialists and Research Institute (FCS) announced its Chief Financial Officer, Nathan H. Walcker, MBA, has been named Chief Executive Officer (CEO). Mr. Walcker succeeds the current CEO, Brad Prechtl, MBA, who is retiring but will continue to serve as a consultant. Mr. Prechtl has...
Cleveland Clinic Cancer Center Oncologists Earn National Recognition as Institution Expands Staff
Cleveland Clinic Cancer Center recently announced news about the following physicians, including the appointment of four new staff members: Shilpa Gupta, MD, received a 2-year, $573,850 grant from the Department of Defense to study biomarkers of response and resistance to immunotherapy and to apply ...
NCI Funds Studies of Impact of Telehealth and Telemedicine Capacity for Rural Patients Amid COVID-19 Pandemic
The National Cancer Institute (NCI) has awarded the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) a supplemental grant (P30) to study the role of telehealth in delivering cancer care during the COVID-19 pandemic. The project will evaluate the impact of telehealth on health outcomes, patient...
Pembrolizumab for First-Line Treatment of Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
On June 29, 2020, pembrolizumab was approved for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) colorectal cancer.1 Supporting Efficacy Data Approval was based on findings in the randomized,...
NRG Oncology Biospecimen Bank Awarded NCI Funding for Next 6 Years
The NRG Oncology Biospecimen Bank will be awarded an additional 6 years of funding from the National Cancer Institute (NCI). This grant will provide biospecimen banking support for the NCI National Clinical Trials Network (NCTN) group NRG Oncology. During the peer-review grant-renewal process, the...
Flossie Wong-Staal, PhD, Molecular Biologist Who Uncovered the Secrets of Human Immunodeficiency Virus, Dies at 73
The origin of the human immunodeficiency virus (HIV) has been traced back to Kinshasa, in the Democratic Republic of Congo, around 1920, when the virus crossed species from chimpanzees to humans. It wasn’t until the 1980s that epidemiologic data began to sum up the number of people who were...
A Pioneering Neurosurgeon Shares Hard-Earned Wisdom Gained Along the Road From the Segregated South
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with noted neurosurgeon Keith L. Black, MD, Chair of Cedars-Sinai Medical Center’s Department of Neurosurgery and Director of the Maxine Dunitz Neurosurgical Institute. During his career, Dr. Black has...
Gemtuzumab Ozogamicin in Pediatric Patients With Newly Diagnosed CD33-Positive AML
On June 16, 2020, the indication of gemtuzumab ozogamicin (Mylotarg) for newly diagnosed CD33-positive acute myeloid leukemia (AML) was extended to include pediatric patients aged 1 month and older.1,2 Supporting Efficacy Data Approval was supported by findings from the phase III AAML0531 trial...
Fox Chase Cancer Center Welcomes New Staff Members
Fox Chase Cancer Center has announced the hiring of three new staff members who will begin their work with the cancer center this month. Brandon Bachert, MD, joins the Department of Diagnostic Imaging as Assistant Professor. He comes to Fox Chase from Albert Einstein Healthcare Network, where he...
American Cancer Society and Flatiron Health Announce Recipients of the Real-World Data Impact Award
Three American Cancer Society (ACS) researchers will receive the Real-World Data Impact Award. The joint grant-making program, supported by the ACS and Flatiron Health, seeks to accelerate cancer research and improve treatment and outcomes for patients. The researchers, already funded by the ACS,...
CICERO Software May Enable Detection of Cancer-Causing Gene Fusions
After years of development, engineering, and enhancement, researchers at St. Jude Children’s Research Hospital in Memphis have made available a software system that enables better detection of gene fusions. The system, called CICERO, offers additional insights into cancers as well as new targets...
Selinexor in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
On June 22, 2020, the oral nuclear export inhibitor selinexor was granted accelerated approval for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic...
Translated Tool From NCCN Measures Mental Health ‘Temperature’ of People With Cancer
The National Comprehensive Cancer Network® (NCCN) recently announced that the NCCN Distress Thermometer has been translated into 46 languages. This free resource helps providers worldwide identify and address the multifactorial aspects of distress patients with cancer can experience. The NCCN...
Neoadjuvant Atezolizumab Plus Chemotherapy Produces High Major and Complete Pathologic Response Rates in Resectable NSCLC
In a phase II study reported in The Lancet Oncology, Catherine A. Shu, MD, of Columbia University Irving Medical Center, and colleagues found that neoadjuvant treatment with atezolizumab plus nab-paclitaxel/carboplatin produced a major pathologic response in 57% of patients and pathologic complete...
Fixed-Dose Subcutaneous Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf in HER2-Positive Breast Cancer
On June 29, 2020, a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO) for subcutaneous injection was approved for the following indications1,2: Use in combination with chemotherapy as neoadjuvant treatment of patients with HER2-positive, locally advanced,...
Dr. Jimmie C. Holland’s Research Has Long Underscored the Importance of Caring for the Whole Patient
Jimmie C. Holland, MD, who served as the inaugural Chairman of the Department of Psychiatry and Behavioral Sciences at Memorial Sloan Kettering Cancer Center, died on December 24, 2017, at the age of 89. The ASCO Post paid tribute to Dr. Holland in its January 25, 2018, issue. Here, as part of our ...
Highlights of Research in Lymphomas Presented During the EHA25 Virtual Congress
To complement The ASCO Post’s continued coverage of the virtual edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), here are a few abstracts selected from the meeting proceedings focusing on clinical research in Hodgkin and marginal zone lymphomas. Omission of...
Tazemetostat for Adults With Relapsed or Refractory Follicular Lymphoma
On June 18, 2020, the EZH2 inhibitor tazemetostat was granted accelerated approval for the treatment of adults with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test, and who have...
NCCN Clinical Practice Guidelines in Oncology: 2020 Updates
In 1996, the National Comprehensive Cancer Network (NCCN) published its first set of Clinical Practice Guidelines in Oncology®, covering eight tumor types. Guidelines are now published for more than 60 tumor types and topics. During the NCCN’s 25th Annual Conference, which was held virtually during ...
